Toomey C, Johnson L, Bowes Rickman C
Prog Retin Eye Res. 2017; 62:38-57.
PMID: 28928087
PMC: 5776047.
DOI: 10.1016/j.preteyeres.2017.09.001.
Muff-Luett M, Nester C
J Pediatr Genet. 2016; 5(1):33-42.
PMID: 27617140
PMC: 4918710.
DOI: 10.1055/s-0036-1572515.
Kaplan B, Ruebner R, Spinale J, Copelovitch L
Intractable Rare Dis Res. 2014; 3(2):34-45.
PMID: 25343125
PMC: 4204535.
DOI: 10.5582/irdr.2014.01001.
Michaux K, Bacchetta J, Javouhey E, Cochat P, Fremaux-Bacchi V, Sellier-Leclerc A
Pediatr Nephrol. 2014; 29(12):2415-9.
PMID: 25149852
DOI: 10.1007/s00467-014-2933-1.
Ozaltin F, Li B, Rauhauser A, An S, Soylemezoglu O, Gonul I
J Am Soc Nephrol. 2013; 24(3):377-84.
PMID: 23274426
PMC: 3582208.
DOI: 10.1681/ASN.2012090903.
Structural basis for engagement by complement factor H of C3b on a self surface.
Morgan H, Schmidt C, Guariento M, Blaum B, Gillespie D, Herbert A
Nat Struct Mol Biol. 2011; 18(4):463-70.
PMID: 21317894
PMC: 3512577.
DOI: 10.1038/nsmb.2018.
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl I, Kavanagh D, McIntosh N, Harris C, Barlow P
J Biol Chem. 2011; 286(13):11082-90.
PMID: 21270465
PMC: 3064162.
DOI: 10.1074/jbc.M110.211839.
Complement control protein factor H: the good, the bad, and the inadequate.
Ferreira V, Pangburn M, Cortes C
Mol Immunol. 2010; 47(13):2187-97.
PMID: 20580090
PMC: 2921957.
DOI: 10.1016/j.molimm.2010.05.007.
The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module.
Schmidt C, Herbert A, Mertens H, Guariento M, Soares D, Uhrin D
J Mol Biol. 2009; 395(1):105-22.
PMID: 19835885
PMC: 2806952.
DOI: 10.1016/j.jmb.2009.10.010.
Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study.
Klein R, Knudtson M, Lee K, Klein B
Arch Ophthalmol. 2009; 127(2):193-9.
PMID: 19204238
PMC: 2737458.
DOI: 10.1001/archophthalmol.2008.551.
Complement factor H: using atomic resolution structure to illuminate disease mechanisms.
Barlow P, Hageman G, Lea S
Adv Exp Med Biol. 2008; 632:117-42.
PMID: 19025119
PMC: 4863441.
Pathogenesis of thrombotic microangiopathies.
Zheng X, Sadler J
Annu Rev Pathol. 2008; 3:249-77.
PMID: 18215115
PMC: 2582586.
DOI: 10.1146/annurev.pathmechdis.3.121806.154311.
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.
Pickering M, Cook H
Clin Exp Immunol. 2008; 151(2):210-30.
PMID: 18190458
PMC: 2276951.
DOI: 10.1111/j.1365-2249.2007.03574.x.
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S
J Clin Invest. 2003; 111(8):1181-90.
PMID: 12697737
PMC: 152934.
DOI: 10.1172/JCI16651.
Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
Sanchez-Corral P, Perez-Caballero D, Huarte O, Simckes A, Goicoechea E, Lopez-Trascasa M
Am J Hum Genet. 2002; 71(6):1285-95.
PMID: 12424708
PMC: 378565.
DOI: 10.1086/344515.
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.
Richards A, Buddles M, Donne R, Kaplan B, Kirk E, Venning M
Am J Hum Genet. 2001; 68(2):485-90.
PMID: 11170896
PMC: 1235281.
DOI: 10.1086/318203.
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.
Gonzalez-Rubio C, Gallardo M, Vera M, Lopez-Trascasa M, Rodriguez de Cordoba S, Sanchez-Corral P
Am J Hum Genet. 2001; 68(2):478-84.
PMID: 11170895
PMC: 1235280.
DOI: 10.1086/318201.
